The Difficulty in Defining the True High-Risk Smoldering Myeloma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39047171.
- Also identified by DOI 10.1158/1078-0432.CCR-24-1382.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Early intervention trials have been initiated for the precursor disease smoldering myeloma (SMM). A recent study showed that genomic complexity varies widely among patients treated for high-risk SMM and is associated with response to triplet therapy, suggesting that established clinical risk scores often fail to discriminate between stable and aggressive disease. See related article by Kazandjian et al., p. 4482.
Medical subject headings
- Smoldering Multiple Myeloma